ARMO BioSciences is a biotechnology and healthcare startup that was founded in 2013. The company received a Venture Round investment on 01 January 2018 from Frazier Healthcare Partners. With a focus on developing novel immuno-oncology therapeutics, ARMO BioSciences has attracted the attention of prominent investors in the healthcare and biotechnology sectors. The company's innovative approach to addressing unmet medical needs in oncology has positioned it as a promising player in the industry. As the company continues to advance its pioneering therapies, it presents an intriguing opportunity for investors seeking exposure to groundbreaking developments in the biotechnology and healthcare space.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | Unknown | 1 |
|
01 Jan 2018 |
| Series C | $67.00M | 10 |
|
29 Aug 2017 |
| Series C | $50.00M | 7 |
|
10 Feb 2016 |
| Series B | $30.00M | 4 |
|
28 May 2014 |
| Series A | $20.00M | 3 |
|
25 Nov 2013 |
No recent news or press coverage available for ARMO BioSciences.
We care about your data, and we'd love to use cookies make your experience better.
